These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 29361984

  • 1. Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression.
    Cherk MH, Kong G, Hicks RJ, Hofman MS.
    Cancer Imaging; 2018 Jan 24; 18(1):3. PubMed ID: 29361984
    [Abstract] [Full Text] [Related]

  • 2. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
    Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, Gabriel M, Kendler D, Waitz D, Widmann G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Apr 24; 40(4):514-23. PubMed ID: 23291643
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B, Asopa R, Basu S.
    Clin Nucl Med; 2014 Jun 24; 39(6):505-10. PubMed ID: 24662668
    [Abstract] [Full Text] [Related]

  • 8. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ.
    J Nucl Med; 2009 Sep 24; 50(9):1427-34. PubMed ID: 19690033
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation.
    Aalbersberg EA, de Wit-van der Veen BJ, Versleijen MWJ, Saveur LJ, Valk GD, Tesselaar MET, Stokkel MPM.
    Eur J Nucl Med Mol Imaging; 2019 Mar 24; 46(3):696-703. PubMed ID: 30097670
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, von Guggenberg E, Decristoforo C, Warwitz B, Widmann G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Feb 24; 40(3):364-72. PubMed ID: 23151915
    [Abstract] [Full Text] [Related]

  • 13. Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study.
    Zhu W, Cheng Y, Wang X, Yao S, Bai C, Zhao H, Jia R, Xu J, Huo L.
    J Nucl Med; 2020 Jun 24; 61(6):897-903. PubMed ID: 31676731
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. 68 Ga-DOTATATE Positron Emission Tomography-Computed Tomography Quantification Predicts Response to Somatostatin Analog Therapy in Gastroenteropancreatic Neuroendocrine Tumors.
    Lee H, Eads JR, Pryma DA.
    Oncologist; 2021 Jan 24; 26(1):21-29. PubMed ID: 32886441
    [Abstract] [Full Text] [Related]

  • 16. Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of 68Ga DOTATOC as Assessed by Dynamic Whole-body PET in Patients with Neuroendocrine Tumors: Implications for Diagnosis and Therapy.
    Lodge MA, Solnes LB, Chaudhry MA, Wahl RL.
    Mol Imaging Biol; 2021 Oct 24; 23(5):766-774. PubMed ID: 33829361
    [Abstract] [Full Text] [Related]

  • 17. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.
    J Nucl Med; 2013 Mar 24; 54(3):364-72. PubMed ID: 23297077
    [Abstract] [Full Text] [Related]

  • 18. Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE.
    Ortega C, Wong RKS, Schaefferkoetter J, Veit-Haibach P, Myrehaug S, Juergens R, Laidley D, Anconina R, Liu A, Metser U.
    J Nucl Med; 2021 Oct 24; 62(10):1406-1414. PubMed ID: 33579805
    [Abstract] [Full Text] [Related]

  • 19. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
    Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, Warwitz B, Gerardo L, Henninger B, Virgolini I, Rodrigues M.
    Eur J Nucl Med Mol Imaging; 2016 Aug 24; 43(9):1585-92. PubMed ID: 26922350
    [Abstract] [Full Text] [Related]

  • 20. Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors.
    Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, Spitzweg C, Boeck S, Unterrainer M, Gildehaus FJ, Böning G, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Bartenstein P.
    Eur J Nucl Med Mol Imaging; 2020 Apr 24; 47(4):870-880. PubMed ID: 31492994
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.